Article thumbnail

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours

By N Sodha, S Bullock, R Taylor, G Mitchell, B Guertl-Lackner, R D Williams, S Bevan, K Bishop, S McGuire, R S Houlston and R A Eeles

Abstract

We have recently shown that the CHEK2*1100delC mutation acts as a low penetrance breast cancer susceptibility allele. To investigate if other CHEK2 variants confer an increased risk of breast cancer, we have screened an affected individual with breast cancer from 68 breast cancer families. Five of these individuals were found to harbour germline variants in CHEK2. Three carried the 1100delC variant (4%). One of these three individuals also carried the missense variant, Arg180His. In the other two individuals, missense variants, Arg117Gly and Arg137Gln, were identified. These two missense variants reside within the Forkhead-associated domain of CHEK2, which is important for the function of the expressed protein. None of these missense variants were present in 300 healthy controls. Microdissected tumours with a germline mutation showed loss of the mutant allele suggesting a mechanism for tumorigenesis other than a loss of the wild type allele. This study provides further evidence that sequence variation in CHEK2 is associated with an increased risk of breast cancer, and implies that tumorigenesis in association with CHEK2 mutations does not involve loss of the wild type allele

Topics: Genetics and Genomics
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2376278
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for ef´Čücient activation of Chk2 in response to ionizing radiation.